P372: DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB

MLA

W. Macaron, et al. “P372: Dismal Outcomes of Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Failure of Both Inotuzumab Ozogamicin and Blinatumomab.” HemaSphere, vol. 6, June 2022, pp. 272–73. EBSCOhost, https://doi.org/10.1097/01.HS9.0000844376.80277.de.

APA

W. Macaron, E. Jabbour, M. Konopleva, F. Ravandi, N. Jain, G. Issa, T. Kadia, K. Sasaki, P. Kebriaei, M. Yilmaz, P. Thompson, K. Takahashi, H. Abbas, W. Wierda, R. Garris, H. Kantarjian, & N. Short. (2022). P372: Dismal Outcomes of Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Failure of Both Inotuzumab Ozogamicin and Blinatumomab. HemaSphere, 6, 272–273. https://doi.org/10.1097/01.HS9.0000844376.80277.de

Chicago

W. Macaron, E. Jabbour, M. Konopleva, F. Ravandi, N. Jain, G. Issa, T. Kadia, et al. 2022. “P372: Dismal Outcomes of Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Failure of Both Inotuzumab Ozogamicin and Blinatumomab.” HemaSphere 6 (June): 272–73. doi:10.1097/01.HS9.0000844376.80277.de.